Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allisartan Isoproxil/Amlodipine in Essential Hypertension
NCT06465264Phase 3Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of allisartan isoproxil, amlodipine in essential hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Apr 2021; status: completed.
02
Drugs
allisartan isoproxilamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06465264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465264.